The world's top drug maker Pfizer said on Monday it has entered into a deal to sell drug maker Biocon biosimilar versions of diabetes treatment insulin.
Under the deal, Pfizer will pay Biocon $200 million up front. Biocon will also be eligible to receive additional development and regulatory milestone payments of up to $150 million plus payments related to sales of these medicines, Pfizer added.
Monday, October 18, 2010
Biocon, Pfizer in $200 mn insulin marketing deal
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment